You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients
|
|---|---|
| Published in |
Radiation Oncology, September 2013
|
| DOI | 10.1186/1748-717x-8-206 |
| Pubmed ID | |
| Authors |
Darius Norkus, Agata Karklelyte, Benedikt Engels, Harijati Versmessen, Romas Griskevicius, Mark De Ridder, Guy Storme, Eduardas Aleknavicius, Ernestas Janulionis, Konstantinas Povilas Valuckas |
| Abstract |
The α/β ratio for prostate cancer is postulated being in the range of 0.8 to 2.2 Gy, giving rise to the hypothesis that there may be a therapeutic advantage to hypofractionation. To do so, we carried out a randomized trial comparing hypofractionated and conventionally fractionated image-guided intensity modulated radiotherapy (IG-IMRT) in high-risk prostate cancer. Here, we report on acute toxicity and quality of life (QOL) for the first 124 randomized patients. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Unknown | 87 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 15% |
| Student > Master | 12 | 13% |
| Student > Doctoral Student | 12 | 13% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Bachelor | 9 | 10% |
| Other | 14 | 16% |
| Unknown | 20 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 36% |
| Physics and Astronomy | 4 | 4% |
| Agricultural and Biological Sciences | 4 | 4% |
| Computer Science | 3 | 3% |
| Nursing and Health Professions | 3 | 3% |
| Other | 16 | 18% |
| Unknown | 27 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2013.
All research outputs
#14,759,250
of 22,719,618 outputs
Outputs from Radiation Oncology
#901
of 2,046 outputs
Outputs of similar age
#116,507
of 196,871 outputs
Outputs of similar age from Radiation Oncology
#17
of 45 outputs
Altmetric has tracked 22,719,618 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,046 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,871 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.